
    
      This is a double blind, randomized, controlled Phase I study of PfCp2.9, an experimental
      malaria vaccine candidate, adjuvanted with Montanide ISA 720.

      The primary objective of this study is to assess the safety and reactogenicity of the vaccine
      in healthy Chinese adult volunteers.
    
  